2. Academic Validation
  3. Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation

Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation

  • J Pharmacol Sci. 2020 Sep;144(1):43-51. doi: 10.1016/j.jphs.2020.07.002.
Yue Ming 1,  Guang Xin 1,  Beihong Ji 2,  Chengji Ji 3,  Zeliang Wei 1,  Boli Zhang 4,  Junhua Zhang 4,  Kui Yu 1,  Xiaoyu Zhang 1,  Shiyi Li 1,  Youping Li 1,  Zhihua Xing 1,  Hai Niu 5,  Wen Huang 6
Affiliations

Affiliations

  • 1 Laboratory of Ethnopharmacology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • 2 Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania, United States.
  • 3 Clinical Laboratory, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
  • 4 Laboratory of Ethnopharmacology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • 5 Laboratory of Ethnopharmacology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: niuhai@scu.edu.cn.
  • 6 Laboratory of Ethnopharmacology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: huangwen@scu.edu.cn.
PMID: 32653340 DOI: 10.1016/j.jphs.2020.07.002
Abstract

Platelet activation is the primary cause of thrombosis. The P2X7 Receptor (P2X7R) is a therapeutic target of thrombosis. However, it is still unknown whether P2X7R activation affects platelet thrombus. Our molecular docking results showed that entecavir as a P2X7R antagonist interacted perfectly with the human P2X7R (hP2X7R) in silico simulation studies. Furthermore, our experimental data revealed that entecavir could act as a P2X7R antagonist to exert cytoprotective effects against platelet activation via protecting mitochondrial function, improving lipid peroxidation and increasing antioxidant activity. Correlated with this, entecavir inhibited platelet aggregation, dense-granule secretion, P-selectin expression, Integrin activation and CA2+ increase. In experimental mouse model, entecavir could significantly inhibit arteriovenous thrombosis and prolong the bleeding time. Furthermore, we found that entecavir had no significant effect on prothrombin time (PT), activated partial Thrombin time (APTT), Thrombin time (TT), fibrinogen (FIB), mean platelet volume (MPV) and platelet counts (PLT). This study demonstrates that entecavir markedly prevents platelet activation and thrombosis through inhibiting P2X7R without affecting coagulation system. Therefore, entecavir may be a potential candidate for treating thrombosis disease.

Keywords

Entecavir; Mitochondria; Oxidative stress; P2X7 receptor; Platelet.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z